Migraine Headache Ibrahim Sales, Pharm.D. Associate Professor of Clinical Pharmacy King Saud University

Slides:



Advertisements
Similar presentations
By Claudine HAMEL-DESNOS, Caen, France
Advertisements

Headache.
Migraine and Dizziness
Headache Guideline Cumbria
Headaches - In Primary Care Dr M Banerjee GP Registrar Tadworth.
Migraine Headaches What you need to know. What is a Migraine headache? Classic migraine – Has an aura 10 to 30 minutes before a migraine Common migraine.
Migraine Lecture 2002 Jin-Hyeun Huh Pharmacy Practice Leader TWH, UHN.
Management of Migraine MIGRAINE - Pattern of recurrent episodes of severe disabling headache associated with nausea and sensitivity to light and who have.
 Migraine is a benign and recurring syndrome of headache, nausea and vomiting, and /or other neurological dysfunction.  Migraine, the most common cause.
 Dr David PB Watson  Hamilton Medical Group Aberdeen.
Migraines Mark Green, MD Clinical Professor Department of Neurology Columbia University New York, NY.
The Basics of Migraines
2008. Diagnostic criteria  At least 10 episodes fulfilling following criteria  Headache lasting 30 mins to 7 days  Has 2 at least 2 of the following.
Prof. Omnia Amin Nayel & Dr. Ishfaq Bukhari. Differentiate between types of headache regarding their symptoms, signs and pathophysiology. Recognize drugs.
Report by Jonathan Cartney.  Under-diagnosed/under-treated  million people diagnosed each year in the United States (Approx 12 percent of US pop.)
Paediatric headaches Mark Weatherall London Headache Centre 2010.
Sarah Hodges, DO Staff Neurologist
Analgesic and Antipyretic Agents
Serotonin syndrome  Sternbach Criteria for Serotonin Syndrome  Recent addition or increase in a known serotonergic agent  Absence of other possible.
Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials by Michel D. Ferrari, Krista I. Roon, Richard B.
Copyright © 2015 Cengage Learning® 1 Chapter 19 Analgesics, Sedatives, and Hypnotics.
Headache and Internal Analgesics. Headaches Most common pain complaint 40% of US population have recurrent HA Classifications:  Primary HA: 90% of HAs,
Anti-migraine Drugs Courtney Geiger Medicinal Chemistry Dr. Buynak November 18, 2004.
Ehab Samara Fedaa Matanes. Pain concentrated on one side of the head A debilitating neurobiological headache disorder Affects 28 million people in the.
Anti-Migraine Drugs Brian Lich April 3 rd, Overview Migraines: What are they? Symptoms? Causes? Migraines: What are they? Symptoms? Causes? History:
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 30 Drugs for Headache.
Acute treatment of migraine Dr Mark Weatherall London Headache Centre 2010.
MIGRAINE BY PROF, AZZA EL-MEDANY MIGRAINE Recurrent attacks of headache. Unilateral, associated with migraine aura ( anorexia, nausea, vomiting, visual.
Diagnosis and management of primary headache
“My migraine always comes back” Presented by: Julio Pascual Neuroscience Area, Service of Neurology, University Hospital Central de Asturias and Ineuropa,
39-year-old woman with ‘monthly’ headaches Presented by: Anne MacGregor Barts Sexual Health Centre, St. Bartholomew’s Hospital, London, UK CLINICAL CASE.
Headache By Dr. Andrew Gutwein We all get ‘em! So why do patients come to the doctor? Severity Worried about brain tumor.
Neurology Lecture 4a Headaches.
Migraine Headaches Migraine Severe, throbbing, vascular headache
Do you ever have one of those days?. The Ultimate Migraine A rhetorical look at treatments, research trials, and why having one is such a headache.
Serious Causes Rarely seen, but not to be missed.
School of Clinical Medicine School of Clinical Medicine UNIVERSITY OF CAMBRIDGE Headache Jane Smith, a 23 year old woman, presents to her GP complaining.
Dr.B.V.Venkataraman Professor in Pharmacology Faculti Perubatan, Shah Alam, Malaysia Ph: /
INCREASED INCIDENCE OF REBOUND HEADACHES FROM THE DISCONTINUED USE OF THE ANTI-MIGRAINE MEDICATION, MAXALT ® Sherry Neff Department of Biological Sciences,
Headache By Dr. Andrew Gutwein. We all get ‘em! So why do patients come to the doctor? Severity Worried about brain tumor.
 Describe the actions, intended effects, and related nursing care for patients receiving CNS Stimulants.  Discuss the nursing process as it relates.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 6 Nonopiod (Nonnarcotic) Analgesics.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 18 Nonopioid Analgesics: Nonsteroidal Anti-Inflammatory Drugs.
Dr David PB Watson GPwSI Hamilton Medical Group Aberdeen
Pain Most common reason people seek health care Tissue damage activates free nerve endings (pain receptors) Generally indicates tissue damage.
Headache (Chapter 52). Background Headache is the 4th most common symptom of outpatient visits Costs between $1 - $17 billion annually Prevalence highest.
Migraine Headaches Migraine – Severe, throbbing, vascular headache – Recurrent unilateral head pain – Combined with neurologic and GI disturbances.
Anxiety A state of tension in response to real or imagined stress or danger situations. Anxiety may manifest itself as Psychic or mental state. Somatic.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 17 Nonopioid Analgesics: Salicylates and Nonsalicylates.
CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.
Management of Primary Headache Disorders. Primary Headache disorders Include all the non-malignant recurrent headache disorders not caused by structural.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Central Nervous System Stimulants and Related.
Miscellaneous Pain Medications Medications for Pain & Inflammation ADN 110/cohort 131.
جامعة الكوفه مركز تطوير التدريس والتدريب الجامعي Tention Headache اعداد د. محمد راضي رديف بورد طب جمله عصبيه كلية الطب – جامعة الكوفه 2015 م.
Analgesics and Antipyretics
Dublin November 13 th 2011 By Dr. Edward O’Sullivan 13-Nov
Headaches in Childhood Maura B. Price MD FAAP FRCPC February 2010
원더스 참고자료 두통. 1 차성 두통에 대한 자료 2 차성 두통에 대한 자료.
Treatment of migraine headache. Introduction Migraine is a severe type of unilateral periodic headache characterized by: 1.Prodorme 2.Aura: mild headache,
MANAGAMENT OF MIGRAINE. Migraine Facts Migraine is one of the common causes of recurrent headaches Migraine is one of the common causes of recurrent headaches.
Drugs for Migraine
Drugs for Headaches 1.
Migraine headache is characterized by unilateral , throbbing or non throbbing headache , associated with nausea, vomiting ,photophobia and phonophobia.
Migraine Headaches Migraine Severe, throbbing, vascular headache
CNS Stimulants.
Approach to Headache Dr. Dua’a Hiasat. Family Medicine Specialist.
pain management Lecture headlines :
Dr sadik al ghazawi Associated professer Neurologist Mrcp,frcp uk
Non opioids pain management
Therapy of the Acute Migraine Attack. Therapy of the Migraine Attack Criteria for efficacy Pain free after 2 hrs Improvement of headache from severe.
Presentation transcript:

Migraine Headache Ibrahim Sales, Pharm.D. Associate Professor of Clinical Pharmacy King Saud University

Epidemiology & Etiology Migraines – 10-15% of adults in the US, 34 million worldwide Tension-Type Headache – 30 – 90% of population per year 5% have them chronically (> 15 attacks /month) – Females > Males

Tension-type vs Migraine Headaches Tension-type headacheMigraine Occurs without warningOccurs after warning signs or aura Pain more likely to be all overPain more likely to be one-sided No throbbingThrobbing No nauseaNausea and/or vomiting No light or noise sensitivityLight and/or noise sensitivity No visual disturbancesVisual disturbances Rare to start during sleepNot uncommon to start during sleep

Clinical Presentation

International Headache Society Diagnostic Criteria Migraine without auraMigraine with aura Diagnostic criteria: Headache lasts 4-72 hours (untreated or unsuccessfully treated) Headache has at least two of the following: Aggravation by or causing avoidance of routine physical activity (e.g. walking) Moderate or severe pain intensity Pulsating quality Unilateral location During headache, at least one of the following: Nausea and/or vomiting Photophobia and phonophobia Not attributed to another disorder History of at least five attacks fulfilling above criteria Recurrent disorder manifesting in headaches of reversible focal neurologic symptoms that usually develop gradually over 5-20 minutes and last for less than 60 minutes Headache with the features of migraine without aura usually follows the aura symptoms Less commonly, headache lacks migrainous features or is completely absent Diagnostic criteria: Aura consisting of at least one of the following, but no motor weakness: Fully reversible dysphasic speech disturbance Sensory symptoms that are fully reversible, including positive features (pins and needles) and/or negative features (numbness) Visual symptoms that are fully reversible, including positive features (flickering lights, spots) and/or negative features (loss of vision) At least two of the following: Homogeneous visual symptoms and/or unilateral sensory symptoms At least one aura symptom develops gradually over 5 minutes or different aura symptoms occur in succession over 5 minutes Each symptom lasts at least 5 minutes, but no longer than 60 minutes Headache fulfilling criteria for migraine without aura begins during the aura or follows aura within 60 minutes Not attributed to another disorder History of at least two attacks fulfilling above criteria

Diagnosis POUND – Pulsatile quality of headache – One-day duration (four to 72 hours) – Unilateral location – Nausea or vomiting – Disabling intensity In a primary care setting, the probability of migraine is 92% in patients who report at least four of the five symptoms The probability decreases to 64% in patients with three of the symptoms and 17 % in patients with two or less symptoms

Treatment Evaluation Migraine Disability Assessment Test (MIDAS) – Validated, seven-item questionnaire to determine the severity of migraine headaches – Addresses limitations in activities at work and home as well as social and leisure activities – The score is a sum of missed days of activities at work/home and reduced productivity over 3 months – Final two questions assess frequency and pain MIDAS Questionnaire

Classification MIDAS questionnaire cont. Grade I (sum of 0 – 5): Minimal or infrequent disability Grade II (sum of 6 – 10): Mild or infrequent disability Grade III (sum of 11 – 20): Moderate disability Grade IV (sum of 21 or greater): Severe disability

Seek Urgent Medical Evaluation New onset of sudden and/or severe pain Onset after 40 years of age Usual pattern gets worse Systemic signs (fever, weight loss) Papilledema Cough, exertion Pregnancy or post partum Cancer, HIV or other immunodeficiency/infection Seizures

Treatment Goals Identify abortive and prophylactic treatments Reduced migraine attack frequency Reduced number of migraine days Reduced attack severity Relieve associated adverse effects Enhance quality of life

Drug Therapy Treatment: – Analgesics APAP, ASA, NSAIDs; Opiods; Caffeine & Metoclopramide – Serotonin (5-HT1) Receptor Agonists – Ergot Alkaloids Prevention – Beta-blockers, CCB – AED, TCA, et al.

Analgesics First-line for mild to moderate migraines – Aspirin – NSAIDs – Acetaminophen – OTC combinations acetaminophen, aspirin & caffeine (Excedrin Migraine) acetaminophen, isometheptene & dichloralphenazone (Midrin) aspirin, caffeine and butalbital* (Fiorinal) acetaminophen, caffeine and butalbital* (Fioricet)

Aspirin MOA: Inhibits prostaglandin synthesis by inhibiting COX-1 and COX-2 enzymes thereby reducing sensitivity of pain receptors to the initiation of pain impulses at the source of inflammation Immediate-release, buffered, enteric coated, effervescent and chewable tablets 650 – 1000 mg every 4 – 6 hours up to 4000 mg Adverse effects: GI bleeding, dyspepsia, epigastric discomfort, nausea, and vomiting; Reye’s syndrome Should be taken with food

NSAIDS MOA: Inhibition of prostaglandin synthesis through peripheral inhibition of COX enzymes Ibuprofen: Immediate release and chewable tablets; capsules – 200 – 400 mg every 4 – 6 hours up to 1200 mg Naproxen: Tablets – 220 mg every 8 – 12 hours up to 660 mg – Longer t 1/2 Adverse effects: GI bleeding, dyspepsia, heartburn, nausea, epigastric pain Should be taken with food

Acetaminophen MOA: Inhibition of prostaglandin synthesis by inhibiting COX enzymes in the CNS Immediate-release, extended-release, effervescent, chewable tablets, capsules, suppositories 325 mg – 1000 mg every 4 – 6 hours – Maximum previously was 4000 mg

Combination Products Acetaminophen, 250 mg/aspirin, 250 mg/caffeine, 65 mg (Excedrin Migraine) – 1 or 2 tablets (or capsules) every 6 hours, not to exceed 8 tablets per day Acetaminophen, 325 mg/dichloralphenazone, 100 mg/isometheptene, 65 mg (Midrin) – 1 to 2 capsules orally every 4 hours; not to exceed 8 capsules per day Potential to cause medication-overuse headache with frequent use

Analgesics Opioids – Studies have demonstrated effectiveness in pain relief – Guidelines for use: Infrequent use in the treatment of moderate-to-severe headaches not responsive to standard medications For acute headache when nonopioid medication has failed or is contraindicated, or in the presence of a coexistent disease or lack of diagnosis As rescue medication for severe, middle-of-the-night headache In patients with no history of abuse Limit use to 1 or 2 treatment days per week. Set strict limits and prescribe small amounts to avoid overuse. Relax restrictions with menstrual migraine Barbiturates – Butalbital; butorphanol – Issues: overuse, drug-induced headache, and withdrawal – Withdrawal symptoms Minor (e.g., restlessness, anxiety, sleep disturbances, tremulousness, and gastric distress) Major ≥400mg/day (e.g., agitation, delirium, psychosis, hypotension, hyperthermia, and seizures)

Serotonin (5-HT1) Receptor Agonists “Triptans” First-line therapy in moderate to severe migraine or mild to moderate migraine unresponsive to analgesics 5-Hydroxytryptamine (5-HT): 5-HT 1B, 5-HT 1D Agonists – MOA: Block release of vasoactive peptides Take early in attack for best effect Most patients prefer oral form (if no N/V) 20-40% will have recurrence within 24 hours – Give second dose of same triptan up to maximal daily dose

Serotonin (5-HT1) Receptor Agonists “Triptans” Sumatriptan (SC, NS, PO) – SC & NS good if associated N/V – Relief at 2 hours depends on dosage form SC = 80%, NS = 60%, PO 50 – 60% Almotriptan (Axert), Eletriptan (Relpax), Rizatriptan (Maxalt), Zolmitriptan (Zomig), Frovatriptan (Frova) – All are similar in effectiveness and tolerability

Triptan Clinical Pearls A 100mg dose of sumatriptan may be more effective than lower doses It is sometimes necessary to increase the dose of an individual agent before judging response Nonresponders to one triptan may respond to another Zolmitriptan tastes “better” Rizatriptan has a quicker onset of action than sumatriptan Frovatriptan, naratriptan, and eletriptan have longer t 1/2 than sumatriptan Matching the pharmacokinetics to the temporal pattern of the migraine – Rapid onset medication for short course migraine vs. long-acting medication for slower onset, long lasting symptoms

Triptans Almotriptan (Axert) – 6.25 to 12.5 mg orally, can be repeated in 2 hours, not to exceed 25 mg per day Eletriptan (Relpax) – 20 to 40 mg orally, can be repeated in > 2 hours, not to exceed 80 mg per day Frovatriptan (Frova) – 2.5 mg orally, can be repeated in 2 hours, not to exceed 7.5 mg per day Naratriptan (Amerge) – 1 to 2.5 mg orally, can be repeated in 2 hours, not to exceed 5 mg per day Rizatriptan (Maxalt) – 5 to 10 mg orally, can be repeated in 2 hours, not to exceed 30 mg per day Sumatriptan (Imitrex) – Intranasal: 5 to 20 mg, can be repeated in 2 hours, not to exceed 40 mg per day – Oral: 25 to 100 mg, can be repeated in 2 hours, not to exceed 200 mg per day – Subcutaneous: 4 to 6 mg, may repeat in 1 hour, not to exceed 12 mg per day Zolmitriptan (Zomig, Zomig-ZMT) – Intranasal: 5 mg, may repeat in 2 hours, not to exceed 10 mg per day – Oral disintegrating tablets: 2.5 mg, can be repeated in 2 hours, not to exceed 10 mg per day – Oral: 1.25 to 2.5 mg, can be repeated in 2 hours, not to exceed 10 mg per day Sumatriptan, 85 mg/naproxen, 500 mg (Trexima) – 1 tablet at onset, may repeat in 2 hours, not to exceed 2 tablets per day

Triptan Adverse Effects Tingling, flushing, dizziness, drowsiness, fatigue & feeling of heaviness, tightness or pressure in chest with all – Uncomfortable but not life threatening… – Highest with Sumatriptan Injection* * Also causes injection reaction Cardiovascular vasoconstriction – Rare: angina, MI, arrhythmia, stroke & death – Contraindications: Coronary, CV or other arterial disease, uncontrolled HTN – Caution with other vascular disease

Triptan Drug Interactions & Issues Avoid giving within 24 h of Ergot, another triptan (additive vasoconstriction) Risk of Serotonin syndrome with SSRI, SNRI’s Need 2 week washout from Monoamine oxidase inhibitors (MAO-I) for some – Rizatriptan, sumatriptan, zolmitriptan CYP-3A4 with Almotriptan, Eletriptan Pregnancy Category C

Ergot Alkaloids Serotonin agonist – vasoconstrictor Less effective than triptans in general, may work in triptan-refractory patients Ergotamine tartrate – Combination with caffeine may have fewer adverse effects than pure ergotamines Dihydroergotamine mesylate – SC, IM, IV or sprayed intranasally – Relief in 2 hours for 50% of patients

Ergot Alkaloids Ergotamine tartrate + Caffeine – 2 tablets at onset of attack, then 1 tablet every ½ hour if needed; max 6 tabs/attack, 10 tabs/week. Dihydroergotamine (DHE; Migranal) – Intranasal: 1 spray in each nostril, repeat once after 15 minutes; not to exceed 4 sprays per attack, 6 sprays per day, 8 sprays per week – IV: 0.5 to 1 mg repeated every 8 hours, or continuous IV infusion totaling 3 mg per 24 hours; not to exceed 3 mg per attack – Subcutaneous: 1 mg every hour; not to exceed 3 mg per day

Ergot Adverse Effects Dihydroergotamine < Ergotamine Nausea / vomiting common Vascular occlusion (MI, gangrene) rare except in overdose Contraindicated in pregnancy Potentiated by beta-blockers, nicotine, triptans – Don’t give triptans/ergot within 24 hrs of each other CYP-3A4 inhibitors – contraindicated with clarithromycin, itraconazole

Prevention Frequent or severe migraine, or those that can’t take / don’t respond to acute treatment Beta-blockers (usual ADE’s, contraindications) – Propranolol, Timolol FDA approved Metoprolol, Nadolol, atenolol work Tricyclic antidepressants (sedation, dry mouth) – Amitriptyline has best data, others used too

Prevention Calcium Channel Blockers – Verapamil shown better than placebo – Interacts with ergots via CYP-3A4 – Don’t use with beta blockers (heart block) Antiepileptic drugs – Valproate, topiramate = best data – Half of patients will have > 50% reduction in frequency of migraines – VPA: Nausea, fatigue, tremor, weight gain & hair loss Liver failure, pancreatitis, hyper-ammonemia et al Others: ACE-I, NSAIDs…

Preventative Evidence

Summary Mild to moderate: non-opioid analgesic – Acetaminophen (esp. if pregnant), ASA, NSAID Moderate to severe: triptan – Sumatriptan SC is fastest, most effective – May try different one if inadequate response – Ergots are not as effective, more toxic Prevention – Beta-blockers, AEDs 1 st line VPA, topiramate work but ADE’s…